Agency Information Collection Activities: Proposed Collection; Comment Request, 19075-19076 [2018-09146]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer at (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
amozie on DSK30RV082PROD with NOTICES
Proposed Project: Government
Performance and Results Act (GPRA)
Client/Participant Outcomes Measure—
(OMB No. 0930–0208)—Revision
SAMHSA is requesting approval to
add 13 new questions to its existing
CSAT Client-level GPRA instrument.
Grantees will only be required to answer
no more than four additional questions,
per CSAT grant awarded, in addition to
the other questions on the instrument.
Currently, the information collected
from this instrument is entered and
stored in SAMSHA’s Performance
Accountability and Reporting System,
which is a real-time, performance
management system that captures
information on the substance abuse
treatment and mental health services
delivered in the United States.
Continued approval of this information
collection will allow SAMHSA to
continue to meet Government
Performance and Results Modernization
Act of 2010 reporting requirements that
quantify the effects and
accomplishments of its discretionary
VerDate Sep<11>2014
18:12 Apr 30, 2018
Jkt 244001
grant programs, which are consistent
with OMB guidance.
SAMHSA and its Centers will use the
data for annual reporting required by
GPRA and comparing baseline with
discharge and follow-up data. GPRA
requires that SAMHSA’s fiscal year
report include actual results of
performance monitoring for the three
preceding fiscal years. The additional
information collected through this
process will allow SAMHSA to: (1)
Report results of these performance
outcomes; (2) maintain consistency with
SAMHSA-specific performance
domains, and (3) assess the
accountability and performance of its
discretionary and formula grant
programs.
Proposed changes include the
addition of 13 questions to the
instrument. The proposed questions are:
1. Behavioral Health Diagnoses—
Please indicate patient’s current
behavioral health diagnoses using the
International Statistical Classification of
Diseases, 10th revision, Clinical
Modification (ICD–10–CM) codes listed
below: (Select from list of Substance
Use Disorder Diagnoses and Mental
Health Diagnoses)
2. [For grantee, at discharge and
follow-up] Which of the following
occurred for the client, as a result of
receiving treatment?
a. Client was reunited with child
(children)
b. Client avoided out of home placement
for child (children)
c. None of the above
3. [For grantee] Please indicate the
following:
a. Was this client diagnosed with an
opioid use disorder? (Yes/No)
i. If yes, indicate which FDAapproved medication the client
received for the treatment of opioid
use disorder. (Methadone,
Buprenorphine, Naltrexone,
Extended-release naltrexone, Client
did not receive an FDA-approved
medication for opioid use disorder)
1. If client received an FDA-approved
medication for opioid use disorder,
indicate the number of days the
client received medication.
b. Was the client diagnosed with an
alcohol use disorder? (Yes/No)
i. If yes, indicate which FDAapproved medication the client
received for alcohol use disorder.
(Naltrexone, Extended-release
Naltrexone, Disulfiram,
Acamprosate, Client did not receive
an FDA-approved medication for
alcohol use disorder)
1. If client received an FDA-approved
medication for alcohol use disorder,
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
19075
indicate the number of days the
client received medication
4. [For client] Did the [insert grantee
name] help you obtain any of the
following benefits?
a. Private health insurance
b. Medicaid
c. SSI/SSDI
d. TANF
e. SNAP
5. [For client] Which of the following
were achieved as a result of receiving
services or supports from [insert grantee
name]?
a. Enrolled in school
b. Enrolled in vocational training
c. Currently employed
d. Living in stable housing
6. [For client] Please indicate the
degree to which you agree or disagree
with the following statement (Strongly
Disagree, Disagree, Undecided, Agree,
Strongly Agree).
a. Receiving treatment in a nonresidential setting has enabled me
to maintain parenting and family
responsibilities while receiving
treatment.
7. [For client] Please indicate the
degree to which you agree or disagree
with the following statement (Strongly
Disagree, Disagree, Undecided, Agree,
Strongly Agree).
a. Receiving treatment in a residential
setting with my child (children)
enabled me to focus on my
treatment without the distractions
of parenting and family
responsibilities.
b. As a result of treatment, I feel I now
have the skills and supports to
balance parenting and managing my
recovery.
8. [For grantee] Please indicate which
type of funding was/will be used to pay
for the SBIRT services provided to this
client. (check all that apply):
a. Current SAMHSA grant funding
b. Other federal grant funding
c. State funding
d. Client’s private insurance
e. Medicaid/Medicare
f. Other (Specify)
9. [For grantee at baseline] If client
screened positive for substance misuse
or a substance use disorder, was the
client assigned to the following types of
services?
1. Brief Intervention (Yes/No)
2. Brief Treatment (Yes/No)
3. Referral to Treatment (Yes/No)
[For grantee at follow-up and
discharge] Did the client receive the
following types of services?
1. Brief Intervention (Yes/No)
2. Brief Treatment (Yes/No)
E:\FR\FM\01MYN1.SGM
01MYN1
19076
Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices
3. Referral to Treatment (Yes/No)
10. [For grantee] Did this client get
screened and referred to treatment for
an opioid use disorder or an alcohol use
disorder? Yes/No
a. If yes, did they receive an FDAapproved medication for the
treatment of opioid use disorder or
alcohol use disorder? Yes/No
i. If yes, specify the FDA-approved
medication (methadone,
buprenorphine, naltrexone,
extended-release naltrexone) for
opioid use disorder.
ii. If yes, specify the FDA-approved
medication (naltrexone, extendedrelease naltrexone, disulfiram,
acamprosate) for alcohol use
disorder.
11. [For client] Did the program
provide the following: (Asked of client
at follow up)
a. HIV test—Yes/No
i. If yes, the result was—Positive/
Negative/Indeterminate/Don’t know
ii. If the result was Positive were you
connected to treatment services—
Yes/No
b. Hepatitis B (HBV) test—Yes/No
i. If yes, the result was—Positive/
Negative/Indeterminate/Don’t know
ii. If the result was Positive were you
connected to treatment services—
Yes/No
c. Hepatitis C (HCV) test—Yes/No
i. If yes, the result was—Positive/
Negative/Indeterminate/Don’t know
ii. If the result was Positive were you
connected to treatment services—
Yes/No
12. [For client] Indicate the degree to
which you agree or disagree with each
of the following statements by using:
Strongly Disagree, Disagree, Neutral,
Agree, Strongly Agree, Not Applicable
a. The use of technology accessed
through (insert grantee or program
name) helped me
i. Communicate with my provider
ii. Reduce my substance use
iii. Manage my mental health
symptoms
iv. Support my recovery
13. [For client] To what extent has
this program improved your quality of
life? (To a Great Extent, Somewhat, Very
Little, Not at All)
TABLE 1—ESTIMATES OF ANNUALIZED HOUR BURDEN
Number of
respondents
SAMHSA tool
Responses
per
respondent
Total
number of
responses
Burden
hours
per response
Total
burden
hours
Baseline Interview Includes SBIRT Brief TX, Referral to
TX, and Program-specific questions ................................
Follow-Up Interview with Program-specific questions 1 .......
Discharge Interview with Program-specific questions 2 .......
SBIRT Program—Screening Only .......................................
SBIRT Program—Brief Intervention Only Baseline .............
SBIRT Program—Brief Intervention Only Follow-Up 1 ........
SBIRT Program—Brief Intervention Only Discharge 2 ........
179,668
143,734
93,427
594,192
111,411
89,129
57,934
1
1
1
1
1
1
1
179,668
143,734
93,427
594,192
111,411
89,129
57,934
0.60
0.60
0.60
0.13
.20
.20
.20
107,801
86,240
56,056
77,245
22,282
17,826
11,587
CSAT Total ...................................................................
885,271
........................
1,269,495
........................
379,037
Note: Numbers may not add to the totals due to rounding and some individual participants completing more than one form.
1 It is estimated that 80% of baseline clients will complete this interview.
2 It is estimated that 52% of baseline clients will complete this interview.
Send comments to Summer King,
SAMHSA Reports Clearance Officer,
5600 Fishers Lane, Room 15E57–B,
Rockville, Maryland 20857, OR email a
copy to summer.king@samhsa.hhs.gov.
Written comments should be received
by July 2, 2018.
Summer King,
Statistician.
[FR Doc. 2018–09146 Filed 4–30–18; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
amozie on DSK30RV082PROD with NOTICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
VerDate Sep<11>2014
18:12 Apr 30, 2018
Jkt 244001
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace.
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N03A, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920)
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 83, Number 84 (Tuesday, May 1, 2018)]
[Notices]
[Pages 19075-19076]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09146]
[[Page 19075]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995 concerning opportunity for public comment on proposed
collections of information, the Substance Abuse and Mental Health
Services Administration (SAMHSA) will publish periodic summaries of
proposed projects. To request more information on the proposed projects
or to obtain a copy of the information collection plans, call the
SAMHSA Reports Clearance Officer at (240) 276-1243.
Comments are invited on: (a) Whether the proposed collections of
information are necessary for the proper performance of the functions
of the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: Government Performance and Results Act (GPRA) Client/
Participant Outcomes Measure--(OMB No. 0930-0208)--Revision
SAMHSA is requesting approval to add 13 new questions to its
existing CSAT Client-level GPRA instrument. Grantees will only be
required to answer no more than four additional questions, per CSAT
grant awarded, in addition to the other questions on the instrument.
Currently, the information collected from this instrument is entered
and stored in SAMSHA's Performance Accountability and Reporting System,
which is a real-time, performance management system that captures
information on the substance abuse treatment and mental health services
delivered in the United States. Continued approval of this information
collection will allow SAMHSA to continue to meet Government Performance
and Results Modernization Act of 2010 reporting requirements that
quantify the effects and accomplishments of its discretionary grant
programs, which are consistent with OMB guidance.
SAMHSA and its Centers will use the data for annual reporting
required by GPRA and comparing baseline with discharge and follow-up
data. GPRA requires that SAMHSA's fiscal year report include actual
results of performance monitoring for the three preceding fiscal years.
The additional information collected through this process will allow
SAMHSA to: (1) Report results of these performance outcomes; (2)
maintain consistency with SAMHSA-specific performance domains, and (3)
assess the accountability and performance of its discretionary and
formula grant programs.
Proposed changes include the addition of 13 questions to the
instrument. The proposed questions are:
1. Behavioral Health Diagnoses--Please indicate patient's current
behavioral health diagnoses using the International Statistical
Classification of Diseases, 10th revision, Clinical Modification (ICD-
10-CM) codes listed below: (Select from list of Substance Use Disorder
Diagnoses and Mental Health Diagnoses)
2. [For grantee, at discharge and follow-up] Which of the following
occurred for the client, as a result of receiving treatment?
a. Client was reunited with child (children)
b. Client avoided out of home placement for child (children)
c. None of the above
3. [For grantee] Please indicate the following:
a. Was this client diagnosed with an opioid use disorder? (Yes/No)
i. If yes, indicate which FDA-approved medication the client
received for the treatment of opioid use disorder. (Methadone,
Buprenorphine, Naltrexone, Extended-release naltrexone, Client did not
receive an FDA-approved medication for opioid use disorder)
1. If client received an FDA-approved medication for opioid use
disorder, indicate the number of days the client received medication.
b. Was the client diagnosed with an alcohol use disorder? (Yes/No)
i. If yes, indicate which FDA-approved medication the client
received for alcohol use disorder. (Naltrexone, Extended-release
Naltrexone, Disulfiram, Acamprosate, Client did not receive an FDA-
approved medication for alcohol use disorder)
1. If client received an FDA-approved medication for alcohol use
disorder, indicate the number of days the client received medication
4. [For client] Did the [insert grantee name] help you obtain any
of the following benefits?
a. Private health insurance
b. Medicaid
c. SSI/SSDI
d. TANF
e. SNAP
5. [For client] Which of the following were achieved as a result of
receiving services or supports from [insert grantee name]?
a. Enrolled in school
b. Enrolled in vocational training
c. Currently employed
d. Living in stable housing
6. [For client] Please indicate the degree to which you agree or
disagree with the following statement (Strongly Disagree, Disagree,
Undecided, Agree, Strongly Agree).
a. Receiving treatment in a non-residential setting has enabled me to
maintain parenting and family responsibilities while receiving
treatment.
7. [For client] Please indicate the degree to which you agree or
disagree with the following statement (Strongly Disagree, Disagree,
Undecided, Agree, Strongly Agree).
a. Receiving treatment in a residential setting with my child
(children) enabled me to focus on my treatment without the distractions
of parenting and family responsibilities.
b. As a result of treatment, I feel I now have the skills and supports
to balance parenting and managing my recovery.
8. [For grantee] Please indicate which type of funding was/will be
used to pay for the SBIRT services provided to this client. (check all
that apply):
a. Current SAMHSA grant funding
b. Other federal grant funding
c. State funding
d. Client's private insurance
e. Medicaid/Medicare
f. Other (Specify)
9. [For grantee at baseline] If client screened positive for
substance misuse or a substance use disorder, was the client assigned
to the following types of services?
1. Brief Intervention (Yes/No)
2. Brief Treatment (Yes/No)
3. Referral to Treatment (Yes/No)
[For grantee at follow-up and discharge] Did the client receive the
following types of services?
1. Brief Intervention (Yes/No)
2. Brief Treatment (Yes/No)
[[Page 19076]]
3. Referral to Treatment (Yes/No)
10. [For grantee] Did this client get screened and referred to
treatment for an opioid use disorder or an alcohol use disorder? Yes/No
a. If yes, did they receive an FDA-approved medication for the
treatment of opioid use disorder or alcohol use disorder? Yes/No
i. If yes, specify the FDA-approved medication (methadone,
buprenorphine, naltrexone, extended-release naltrexone) for opioid use
disorder.
ii. If yes, specify the FDA-approved medication (naltrexone,
extended-release naltrexone, disulfiram, acamprosate) for alcohol use
disorder.
11. [For client] Did the program provide the following: (Asked of
client at follow up)
a. HIV test--Yes/No
i. If yes, the result was--Positive/Negative/Indeterminate/Don't
know
ii. If the result was Positive were you connected to treatment
services--Yes/No
b. Hepatitis B (HBV) test--Yes/No
i. If yes, the result was--Positive/Negative/Indeterminate/Don't
know
ii. If the result was Positive were you connected to treatment
services--Yes/No
c. Hepatitis C (HCV) test--Yes/No
i. If yes, the result was--Positive/Negative/Indeterminate/Don't
know
ii. If the result was Positive were you connected to treatment
services--Yes/No
12. [For client] Indicate the degree to which you agree or disagree
with each of the following statements by using: Strongly Disagree,
Disagree, Neutral, Agree, Strongly Agree, Not Applicable
a. The use of technology accessed through (insert grantee or program
name) helped me
i. Communicate with my provider
ii. Reduce my substance use
iii. Manage my mental health symptoms
iv. Support my recovery
13. [For client] To what extent has this program improved your
quality of life? (To a Great Extent, Somewhat, Very Little, Not at All)
Table 1--Estimates of Annualized Hour Burden
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Burden hours Total burden
SAMHSA tool respondents respondent of responses per response hours
----------------------------------------------------------------------------------------------------------------
Baseline Interview Includes 179,668 1 179,668 0.60 107,801
SBIRT Brief TX, Referral to TX,
and Program-specific questions.
Follow-Up Interview with Program- 143,734 1 143,734 0.60 86,240
specific questions \1\.........
Discharge Interview with Program- 93,427 1 93,427 0.60 56,056
specific questions \2\.........
SBIRT Program--Screening Only... 594,192 1 594,192 0.13 77,245
SBIRT Program--Brief 111,411 1 111,411 .20 22,282
Intervention Only Baseline.....
SBIRT Program--Brief 89,129 1 89,129 .20 17,826
Intervention Only Follow-Up \1\
SBIRT Program--Brief 57,934 1 57,934 .20 11,587
Intervention Only Discharge \2\
-------------------------------------------------------------------------------
CSAT Total.................. 885,271 .............. 1,269,495 .............. 379,037
----------------------------------------------------------------------------------------------------------------
Note: Numbers may not add to the totals due to rounding and some individual participants completing more than
one form.
\1\ It is estimated that 80% of baseline clients will complete this interview.
\2\ It is estimated that 52% of baseline clients will complete this interview.
Send comments to Summer King, SAMHSA Reports Clearance Officer,
5600 Fishers Lane, Room 15E57-B, Rockville, Maryland 20857, OR email a
copy to [email protected]. Written comments should be received
by July 2, 2018.
Summer King,
Statistician.
[FR Doc. 2018-09146 Filed 4-30-18; 8:45 am]
BILLING CODE 4162-20-P
